166 related articles for article (PubMed ID: 21644238)
1. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer.
Ansari D; Rosendahl A; Elebro J; Andersson R
Br J Surg; 2011 Aug; 98(8):1041-55. PubMed ID: 21644238
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
[TBL] [Abstract][Full Text] [Related]
3. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
Yako YY; Kruger D; Smith M; Brand M
PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
[No Abstract] [Full Text] [Related]
5. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
Jamieson NB; Carter CR; McKay CJ; Oien KA
Clin Cancer Res; 2011 May; 17(10):3316-31. PubMed ID: 21444679
[TBL] [Abstract][Full Text] [Related]
6. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
7. Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
Gebauer F; Kemper M; Sauter G; Prehm P; Schumacher U
PLoS One; 2017; 12(6):e0178703. PubMed ID: 28582436
[TBL] [Abstract][Full Text] [Related]
8. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma.
Zhou L; Lu J; Liang ZY; Zhou WX; Yuan D; Li BQ; You L; Guo JC; Zhao YP
J Surg Oncol; 2018 Dec; 118(7):1115-1121. PubMed ID: 30261114
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.
Sakugawa C; Haruyama Y; Tanaka H; Fukushima T; Kawaguchi M; Kataoka H
BMC Res Notes; 2017 Dec; 10(1):674. PubMed ID: 29202869
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in pancreatic ductal adenocarcinoma.
Gallego J; López C; Pazo-Cid R; López-Ríos F; Carrato A
Clin Transl Oncol; 2017 Dec; 19(12):1430-1437. PubMed ID: 28616721
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
[TBL] [Abstract][Full Text] [Related]
12. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.
Yanagisawa N; Ichinoe M; Mikami T; Nakada N; Hana K; Koizumi W; Endou H; Okayasu I
J Clin Pathol; 2012 Nov; 65(11):1019-23. PubMed ID: 22813728
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
[TBL] [Abstract][Full Text] [Related]
15. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
